clinical trial · NCT05109234
A Study to Test the Long-term Safety, Tolerability and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
UCB Biopharma SRL·phase3·completed·n = 84
Childhood Absence EpilepsyJuvenile Absence EpilepsyBrivaracetam Film-coated tabletBrivaracetam oral solution
brief summary
The purpose of the study is to investigate the long-term safety, tolerability and efficacy of brivaracetam in pediatric study participants with childhood absence epilepsy (CAE) or juvenile absence epilepsy (JAE).
started
Mar 30, 2022
primary completion
Mar 18, 2025
completion
Mar 18, 2025
last updated
Oct 22, 2025
official title
A Multicenter, Open-Label, Single-Arm Study to Evaluate Long-Term Safety, Tolerability, and Efficacy of Brivaracetam in Study Participants 2 to 26 Years of Age With Childhood Absence Epilepsy or Juvenile Absence Epilepsy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol